Main Conference Day 2Tuesday, 16 December 2025 - PT (Pacific Time, GMT-08:00)

Gyes Bv is a science-driven biotech start-up committed to exploring new frontiers in antibody therapeutics. We developed the Multispecific Antibody Platform, which we use to discover and develop precision multifunctional antibodies that build on novel insights in avidity engineering. Here I will discuss our progress in designing antibodies that become conditionally active upon binding to combinations of targets co-expressed on select cell populations.

Despite advances in cancer therapeutics, new protein targets and targeting approaches for drug development are needed. We developed a high-resolution proximity labeling technology using photocatalyst-generated reactive probes to label discrete cell surface protein microenvironments. Utilizing our platform to identify proteins inherently proximal to EGFR, we identified CDCP1. This led to the development of IDP-001, a novel bispecific ADC targeting EGFR and CDCP1. Identification and characterization of IDP-001 will be presented.

Despite the curative potential of cancer immunotherapy, most patients do not benefit from existing treatments. Glyco-immune checkpoints – interactions of cancer glycans with inhibitory glycan-binding receptors called lectins – have emerged as prominent mechanisms of resistance to molecular and cellular immunotherapies. I will describe development of antibody-lectin chimeras: a biologic framework for glyco-immune checkpoint blockade that is now moving toward the clinic.

Celiac disease is an autoimmune disorder in which ingestion of gluten damages the small intestine in genetically predisposed patients carrying HLA-DQ2.5 haplotype. DONQ52 is a novel neutralizing antibody that exhibits broad cross-reactivity against multiple gluten peptide/HLA-DQ2.5 complexes. In this presentation, we will present the identification of the lead antibody, its multidimensional optimization process, and the key characteristics of DONQ52.

Oral delivery of antibodies directly to intestinal tissue would allow IBD treatment without systemic exposure or injections. Sorriso VHH single domain antibodies are engineered for stability among intestinal and inflammatory proteases, enabling oral dosing. SOR102 is an anti-TNF/IL-23p19 bi-specific formulated into room-temperature stable enteric-coated mini-tablets. On exposure to intestinal trypsin, the SOR102 trypsin-labile central linker is cleaved, liberating each monomer for intestinal tissue entry. SOR102 was evaluated in healthy volunteers and ulcerative colitis (UC) patients in a Phase 1 first-in-human study (NCT06080048). SOR102 was safe and well tolerated with minimal systemic exposure. However, consistent micromolar levels of active monomers were detected in UC patient feces and monomers were measured in UC colonic tissues. In the SOR102 BID arm, there was a strong alignment between UC clinical activity, tissue [drug], and pharmacodynamic outcomes. Thus, SOR102 delivered local TNFa/IL-23 inhibition within the inflamed GI tissue of UC patients, while limiting systemic exposure.